Johnson & Johnson's
Centocor unit received an expanded indication for its drug Remicade. The treatment, which was approved in 1998 for Crohn's disease and in 2005 for ulcerative colitis, can now be marketed as a treatment to maintain ulcerative colitis remission. Shares of J&J dipped 15 cents, or 0.2%, to $68.
shares skyrocketed after the company said its drug BiovaxID improved disease-free survival in patients with relapsed follicular non-Hodgkin's lymphoma following unsuccessful chemotherapy treatment, with or without Rituxan. Accentia's shares were up 54.5% to $4.45. Rituxan is sold by
( DNA) and
( AVII) were up 9.1% to $4.08 after the company presented positive trial results on AVI-4557, a chemical found to alter drug metabolism in humans. Controlling the rate of drug metabolism could reduce the amount of a drug that needs to be taken.
announced plans to sell its surgery centers and use the proceeds to reduce debt as a part of its restructuring plans. Although the centers complemented the health care company's overall business, they aren't central to its mission, PainCare said in a press release. Shares jumped 22.6% to $1.63 on the news.
Also rising were
, up 2.8% to $65.94,
, 1.1% higher to $55.82,
( BVF), rising 1.4% to $15.90,
, up 2.7% to $27.61, and
, gaining 6.9% to $10.66.
Among health stocks falling were
, 2.9% lower to $33.74,
, down 6.9% to $3.25, and
, whose shares were dropping 6.3% to $6.14.